Novonesis’ Post

Novonesis achieves key milestone with approval of 2'-FL HMO in China     We are pleased to announce the approval of the first of our five commercialized HMOs in China. This is an important step towards introducing additional HMOs (Human Milk Oligosaccharides) of our MyOli® 5 HMO Mix.    With the nutrition fortifier approval of our first HMO (2’-FL), infant formula producers in China can now file for, and gain approval of recipes containing our 2’-FL. Beyond infant formula, the approval also enables the use in other prepared milk powder, older infant and young children formula, as well as infant formula for special medical purposes.     At Novonesis, we are excited about the prospect of bringing the great benefits of our HMOs to families and infants across the Chinese market.    “Securing the approval of 2'-FL in China is a key milestone for us on our journey to bring the benefits of our HMO solutions to infants in China and advancing HMO science in collaboration with our infant formula partners in the region,” says Thomas Stenfeldt Batchelor, Senior Vice President of Advanced Health and Protein Solutions at Novonesis.    Learn more in the press release: https://lnkd.in/d6_jFaV8     #biosolutions #HMO #novonesis